News Report | November 23, 2021
Pear Therapeutics reSET-O Cut All Cause Hospital Encounters By 34%
Consumers with opioid addiction who engaged with Pear Therapeutics’ reSET-O® for 12 weeks of treatment had a 34% lower incidence of all-cause hospital encounters over the next nine months following treatment compared to those who were prescribed but did not engage with reSET-O. reSET-O is currently the only prescription digital therapeutic (PDT) approved by the U.S Food and Drug Administration (FDA) as treatment for opioid use disorder. Over the nine months after being prescribed re-SET-O, those who engaged with re-SET-O had 0.732 unique hospital encounters per person compared to 1 . . .